NO2020001I1 - Gilteritinib or a salt thereof - Google Patents
Gilteritinib or a salt thereofInfo
- Publication number
- NO2020001I1 NO2020001I1 NO2020001C NO2020001C NO2020001I1 NO 2020001 I1 NO2020001 I1 NO 2020001I1 NO 2020001 C NO2020001 C NO 2020001C NO 2020001 C NO2020001 C NO 2020001C NO 2020001 I1 NO2020001 I1 NO 2020001I1
- Authority
- NO
- Norway
- Prior art keywords
- gilteritinib
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009113936 | 2009-05-08 | ||
PCT/JP2010/057751 WO2010128659A1 (en) | 2009-05-08 | 2010-05-06 | Diamino heterocyclic carboxamide compound |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2020001I1 true NO2020001I1 (en) | 2020-01-16 |
Family
ID=43050157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO15189570A NO3009428T3 (en) | 2009-05-08 | 2010-05-06 | |
NO2020001C NO2020001I1 (en) | 2009-05-08 | 2020-01-16 | Gilteritinib or a salt thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO15189570A NO3009428T3 (en) | 2009-05-08 | 2010-05-06 |
Country Status (29)
Country | Link |
---|---|
US (2) | US8969336B2 (en) |
EP (2) | EP2428508B9 (en) |
JP (1) | JP5364159B2 (en) |
KR (1) | KR101614572B1 (en) |
CN (1) | CN102421761B (en) |
AU (1) | AU2010245545B2 (en) |
BR (1) | BRPI1011838B8 (en) |
CA (1) | CA2760061C (en) |
CY (3) | CY1117546T1 (en) |
DK (2) | DK2428508T3 (en) |
ES (2) | ES2667706T3 (en) |
FR (1) | FR20C1003I2 (en) |
HK (1) | HK1219105A1 (en) |
HR (2) | HRP20151435T8 (en) |
HU (3) | HUE038515T2 (en) |
IL (1) | IL216132A (en) |
LT (2) | LT3009428T (en) |
LU (1) | LUC00147I2 (en) |
MX (1) | MX2011011875A (en) |
NL (1) | NL301028I2 (en) |
NO (2) | NO3009428T3 (en) |
PL (2) | PL2428508T3 (en) |
PT (2) | PT2428508E (en) |
RS (2) | RS54552B1 (en) |
SI (2) | SI3009428T1 (en) |
SM (1) | SMT201600075B (en) |
TW (1) | TWI484961B (en) |
WO (1) | WO2010128659A1 (en) |
ZA (1) | ZA201108642B (en) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120208824A1 (en) * | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
ES2546502T3 (en) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pyrimidin-5-yl-carboxamides as inhibitors of syk or JAK kinases |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2534335T3 (en) | 2010-05-20 | 2015-04-21 | Array Biopharma, Inc. | Macrocyclic compounds as Trk kinase inhibitors |
BR112013003388A2 (en) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | besylate salt of a btk inhibitor |
JP2014005206A (en) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | Arylamino heterocyclic carboxamide compound |
WO2012061415A1 (en) * | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
MX2013004894A (en) | 2010-11-01 | 2013-10-17 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof. |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
CN102285969B (en) * | 2011-06-28 | 2013-06-19 | 山东大学 | N-1-substituted piperidin-4-arylamine derivatives and preparation method and use thereof |
BR112014004213A2 (en) | 2011-08-23 | 2017-06-20 | Found Medicine Inc | new kif5b-ret fusion molecules and their uses |
EP2770830A4 (en) | 2011-10-28 | 2015-05-27 | Celgene Avilomics Res Inc | Methods of treating a bruton's tyrosine kinase disease or disorder |
US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
CN104080774B (en) | 2012-01-17 | 2017-02-22 | 安斯泰来制药株式会社 | Pyrazine carboxamide compound |
US9108927B2 (en) | 2012-03-15 | 2015-08-18 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
CA2866852C (en) | 2012-03-15 | 2020-12-29 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
AU2013344049B2 (en) * | 2012-11-06 | 2017-12-21 | Fochon Pharmaceuticals, Ltd. | ALK kinase inhibitors |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
MX2015009952A (en) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Erk inhibitors and uses thereof. |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
CN104262328B (en) * | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | The compound of suppression BTK and/or JAK3 kinase activity |
CN113712989A (en) | 2013-10-11 | 2021-11-30 | 艾丽奥斯生物制药有限公司 | Substituted nucleosides, nucleotides and analogs thereof |
BR112016008632A8 (en) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | heteroaryl compounds as btk inhibitors, their uses, and pharmaceutical composition |
AU2014360446A1 (en) * | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CA2935944A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
CN113425727A (en) * | 2014-02-04 | 2021-09-24 | 安斯泰来制药株式会社 | Pharmaceutical composition containing diaminoheterocyclic carboxamide compound as active ingredient |
CN104016977B (en) * | 2014-06-13 | 2016-06-22 | 山东大学 | A kind of replacement thiadiazine diketone derivative and preparation method thereof and application |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
JP6903577B2 (en) | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ,エルエルシー | Method for measuring inhibition of c-Jun N-terminal kinase in skin |
CA3210612A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US20180022710A1 (en) | 2015-01-29 | 2018-01-25 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
FI3318259T3 (en) | 2015-07-03 | 2023-03-20 | Astellas Pharma Inc | Stable pharmaceutical composition for oral administration |
DK3322706T3 (en) | 2015-07-16 | 2021-02-01 | Array Biopharma Inc | SUBSTITUTED PYRAZOLO [1,5-A] PYRIDINE COMPOUNDS AS RIGHT CHINESE INHIBITORS |
CN105001096B (en) * | 2015-07-21 | 2017-07-21 | 沈阳化工研究院有限公司 | A kind of method for preparing 4 amino N alkylbenzylamines |
WO2017019487A1 (en) | 2015-07-24 | 2017-02-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
ES2894691T3 (en) * | 2015-11-04 | 2022-02-15 | Astellas Pharma Inc | Pharmaceutical composition for immunotherapy and/or immunostimulation purposes containing heterocyclic diamino-carboxamide compound as active ingredient |
US20190099413A1 (en) | 2016-02-26 | 2019-04-04 | Ono Pharmaceutical Co., Ltd. | Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination |
CN106083821B (en) * | 2016-06-22 | 2019-01-11 | 上海皓元生物医药科技有限公司 | 3,5- of one kind, bis- substitutions-pyrazine -2- benzamide compound synthetic method |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
CN110267960B (en) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
CN111093640A (en) | 2017-05-17 | 2020-05-01 | 国家健康与医学研究院 | FLT3 inhibitors for improving opioid pain therapy |
CN109384774B (en) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | Polysubstituted pyrazine/triazine amide compounds and preparation method and application thereof |
EP3673907A4 (en) | 2017-08-23 | 2020-08-19 | ONO Pharmaceutical Co., Ltd. | Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component |
WO2019074116A1 (en) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient |
JP7061195B2 (en) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [3,4-d] pyrimidine compound as a RET kinase inhibitor |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
JP7492742B2 (en) * | 2018-03-28 | 2024-05-30 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | Substituted diaminoheterocyclic carboxamide compounds, compositions containing same and uses thereof |
CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
WO2020063856A1 (en) * | 2018-09-30 | 2020-04-02 | 南京明德新药研发有限公司 | 3,9- diazaspiro[5,5] undecane compound as flt3 and axl inhibitors |
EP3870579A4 (en) * | 2018-10-22 | 2022-10-19 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
JP7455810B2 (en) | 2019-03-13 | 2024-03-26 | 大塚製薬株式会社 | Method for introducing deuterated lower alkyl into the amine moiety of a compound containing a secondary amine |
KR20210148252A (en) | 2019-04-03 | 2021-12-07 | 아스텔라스세이야쿠 가부시키가이샤 | pharmaceutical composition |
CN115380024B (en) * | 2020-03-30 | 2024-03-15 | 南京明德新药研发有限公司 | Crystalline forms of diazaspiropyran compounds |
CN111423387B (en) * | 2020-05-11 | 2022-03-08 | 苏州康纯医药科技有限公司 | Preparation method of Giltertinib key intermediate |
JP2023528859A (en) * | 2020-06-01 | 2023-07-06 | ウィゲン・バイオメディシン・テクノロジー・(シャンハイ)・カンパニー・リミテッド | New pyrazine compound |
WO2022009235A1 (en) * | 2020-07-10 | 2022-01-13 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of gilteritinib fumarate |
CN113943288A (en) * | 2020-07-17 | 2022-01-18 | 微境生物医药科技(上海)有限公司 | 5, 6-dihydropyrazino [2,3-c ] isoquinoline compounds |
CN112225703B (en) * | 2020-09-28 | 2022-03-11 | 广州智睿医药科技有限公司 | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity |
TW202227418A (en) * | 2020-10-12 | 2022-07-16 | 大陸商四川海思科製藥有限公司 | Heterocyclic derivative and medical application thereof |
WO2023027966A1 (en) * | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
EP4370506A1 (en) | 2021-12-30 | 2024-05-22 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
WO2023178094A2 (en) * | 2022-03-14 | 2023-09-21 | Purdue Research Foundation | Spleen tyrosine kinase inhibitor, composition, and methods of use |
WO2023225005A1 (en) * | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
CN115124590A (en) * | 2022-07-05 | 2022-09-30 | 武汉大学中南医院 | PROTAC compound for targeted degradation of FLT3-ITD mutant protein and preparation method and application thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1184376E (en) * | 1999-06-09 | 2005-04-29 | Yamanouchi Pharma Co Ltd | NEW HETEROCYCLIC DERIVATIVES OF CARBOXAMIDE |
AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
AU2003244098A1 (en) | 2002-06-28 | 2004-01-19 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxa mide derivative |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2008013499A (en) | 2006-07-06 | 2008-01-24 | Sankyo Co Ltd | 5-cyanonicotinamide derivative |
WO2008016660A2 (en) * | 2006-08-02 | 2008-02-07 | Xanthus Pharmaceuticals, Inc. | Imidazoacridine compounds for treating leukemias |
WO2008024974A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrimidine and pyrazine derivatives |
EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
ES2633318T3 (en) | 2006-10-23 | 2017-09-20 | Cephalon, Inc. | Bicyclic derivatives fused 2,4-diaminopyrimidine as inhibitors of ALK and c-Met |
AU2007333394C1 (en) | 2006-12-08 | 2011-08-18 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
US20100144706A1 (en) | 2006-12-22 | 2010-06-10 | Boehringer Ingelheim International Gmbh | Compounds |
TWI389893B (en) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | Di (arylamino) ary1 compound |
WO2009012421A1 (en) | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
CN101827848B (en) | 2007-08-08 | 2012-11-07 | 葛兰素史密丝克莱恩有限责任公司 | 2- [ (2-{phenylamino}-1H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as iIGF-1R inhibitors for the treatment of cancer |
WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
US8426417B2 (en) | 2007-09-28 | 2013-04-23 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
US20090270418A1 (en) | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
AU2009233963B2 (en) | 2008-04-07 | 2011-10-06 | Irm Llc | Compounds and compositions as kinase inhibitors |
CA2720946C (en) | 2008-04-07 | 2013-05-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
SG2014015085A (en) | 2008-04-16 | 2014-06-27 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
JP5705720B2 (en) * | 2008-04-16 | 2015-04-22 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 2,6-Diamino-pyrimidin-5-yl-carboxamide as SYK or JAK kinase inhibitor |
SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
-
2010
- 2010-05-06 MX MX2011011875A patent/MX2011011875A/en active IP Right Grant
- 2010-05-06 SI SI201031651T patent/SI3009428T1/en unknown
- 2010-05-06 DK DK10772177.1T patent/DK2428508T3/en active
- 2010-05-06 RS RS20160032A patent/RS54552B1/en unknown
- 2010-05-06 WO PCT/JP2010/057751 patent/WO2010128659A1/en active Application Filing
- 2010-05-06 TW TW099114522A patent/TWI484961B/en active
- 2010-05-06 PT PT107721771T patent/PT2428508E/en unknown
- 2010-05-06 ES ES15189570.3T patent/ES2667706T3/en active Active
- 2010-05-06 EP EP10772177.1A patent/EP2428508B9/en active Active
- 2010-05-06 HU HUE15189570A patent/HUE038515T2/en unknown
- 2010-05-06 CA CA2760061A patent/CA2760061C/en active Active
- 2010-05-06 NO NO15189570A patent/NO3009428T3/no unknown
- 2010-05-06 US US13/266,164 patent/US8969336B2/en active Active
- 2010-05-06 JP JP2011512353A patent/JP5364159B2/en active Active
- 2010-05-06 CN CN201080020181.4A patent/CN102421761B/en active Active
- 2010-05-06 HU HUE10772177A patent/HUE026647T2/en unknown
- 2010-05-06 PL PL10772177T patent/PL2428508T3/en unknown
- 2010-05-06 BR BRPI1011838A patent/BRPI1011838B8/en active IP Right Grant
- 2010-05-06 PT PT151895703T patent/PT3009428T/en unknown
- 2010-05-06 PL PL15189570T patent/PL3009428T3/en unknown
- 2010-05-06 DK DK15189570.3T patent/DK3009428T3/en active
- 2010-05-06 EP EP15189570.3A patent/EP3009428B1/en active Active
- 2010-05-06 SI SI201031107T patent/SI2428508T1/en unknown
- 2010-05-06 LT LTEP15189570.3T patent/LT3009428T/en unknown
- 2010-05-06 ES ES10772177.1T patent/ES2559230T3/en active Active
- 2010-05-06 KR KR1020117026122A patent/KR101614572B1/en active IP Right Review Request
- 2010-05-06 AU AU2010245545A patent/AU2010245545B2/en active Active
- 2010-05-06 RS RS20180358A patent/RS57045B1/en unknown
-
2011
- 2011-11-03 IL IL216132A patent/IL216132A/en active Protection Beyond IP Right Term
- 2011-11-24 ZA ZA2011/08642A patent/ZA201108642B/en unknown
-
2014
- 2014-08-29 US US14/472,959 patent/US9487491B2/en active Active
-
2015
- 2015-12-30 HR HRP20151435TT patent/HRP20151435T8/en unknown
-
2016
- 2016-01-27 CY CY20161100072T patent/CY1117546T1/en unknown
- 2016-03-16 SM SM201600075T patent/SMT201600075B/en unknown
- 2016-06-21 HK HK16107176.3A patent/HK1219105A1/en unknown
-
2018
- 2018-03-01 HR HRP20180368TT patent/HRP20180368T1/en unknown
- 2018-03-27 CY CY20181100350T patent/CY1120367T1/en unknown
-
2020
- 2020-01-16 NO NO2020001C patent/NO2020001I1/en unknown
- 2020-01-17 NL NL301028C patent/NL301028I2/en unknown
- 2020-01-21 LT LTPA2020002C patent/LTC2428508I2/en unknown
- 2020-01-22 CY CY2020004C patent/CY2020004I1/en unknown
- 2020-02-04 FR FR20C1003C patent/FR20C1003I2/en active Active
- 2020-02-06 LU LU00147C patent/LUC00147I2/fr unknown
- 2020-02-20 HU HUS2000005C patent/HUS000511I2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2020001I1 (en) | Gilteritinib or a salt thereof | |
NO2021013I1 (en) | filgotinib or a salt thereof | |
NL301193I2 (en) | tebentafusp | |
NL301164I2 (en) | sacituzumab govitecan | |
NO2020037I1 (en) | alpelisib or a pharmaceutically acceptable salt thereof | |
NO2019024I1 (en) | Brigatinib or a pharmaceutically acceptable salt thereof | |
NO2017026I2 (en) | Alektinib or salt or solvate thereof | |
NO2017057I1 (en) | pibrentasvir or a pharmaceutically acceptable salt thereof | |
NO2017059I2 (en) | ribosyclib or a pharmaceutically acceptable salt thereof | |
NO2017024I1 (en) | Elosulfase alfa or a pharmaceutically acceptable salt thereof | |
NO2019019I1 (en) | Doravirin or a pharmaceutically acceptable salt thereof | |
DE112010002949A5 (en) | Kupplungstastpunkte | |
DE102009037898A8 (en) | gripper | |
BRPI1008827A2 (en) | deisobutenizer | |
FR2958801B1 (en) | BIOPILE A GLUCOSE | |
BRPI1014968A2 (en) | underreader | |
DE112010002728A5 (en) | Turboinhalator | |
DE112009005323A5 (en) | Hebelarmprüfmaschine | |
DE112009005462T8 (en) | Lenkungsssteuervorrichtung | |
BR112012004964A2 (en) | gyrocopter | |
BRPI1008070A2 (en) | tricianoboratos | |
DE112010003255A5 (en) | Fördergutverteiler | |
BRPI1010159A2 (en) | bistuti | |
FR2946497B1 (en) | AUTONOMOUS ELAGUE | |
BR112012003616A2 (en) | methylpyrroloprimidinecarboxamides |